Partnership to Advance Nation’s Clinical Research Capabilities

PUTRAJAYA, 4 JANUARY 2024 – Clinical Research Malaysia (CRM) and the Pharmaceutical Association of Malaysia (PhAMA) have entered a strategic partnership to propel the development of clinical research talents and skills in Malaysia. The MoU was formalized earlier today during CRM’s Clinical Research Excellence in Early Phase and People Development event in Ministry of Health office.

The MOU was signed by Dr Akhmal Yusof, Chief Executive Officer of CRM, and Ms Kam Ai Teng, President of PhAMA and was witnessed by the Minister of Health, Datuk Seri Dr Dzulkefly Ahmad. Under the MoU, PhAMA will support CRM through the provision of proteges on an annual basis for the next three years, effective this year.

The partnership will be driven through the CRM’s Centre of Excellence (CoE), which aims to enhance the nation’s clinical research capabilities in building skilled study coordinators profession. This initiative will pave the way for fresh graduates to begin their career in clinical research, aligning with the Pharmaceutical Sector’s Research and Development (R&D) objectives outlined in the New Industrial Master Plan (NIMP) 2030.

“The establishment of the CRM’s Centre of Excellence further solidifies the organizations’ dedication to shaping the future of clinical research in Malaysia. Through collaborative efforts, CRM and PhAMA are poised to contribute significantly to the advancement of healthcare and the pharmaceutical sector in the country,” said Datuk Seri Dr Dzulkefly during his speech.

Ms. Kam Ai Teng, President of PhAMA, echoed this sentiment, highlighting the crucial role of innovation and research in the pharmaceutical industry. “PhAMA is enthusiastic about contributing to the clinical research landscape in Malaysia. The fact that the top five sponsors of new sponsored research in the last five years are all PhAMA members attests to our steadfast commitment to advancing healthcare through research and development,” Ms. Kam added.